Katarzyna Magiera‐Mularz

2.5k total citations
37 papers, 1.9k citations indexed

About

Katarzyna Magiera‐Mularz is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Katarzyna Magiera‐Mularz has authored 37 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 12 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Katarzyna Magiera‐Mularz's work include Cancer Immunotherapy and Biomarkers (25 papers), CAR-T cell therapy research (17 papers) and Peptidase Inhibition and Analysis (9 papers). Katarzyna Magiera‐Mularz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), CAR-T cell therapy research (17 papers) and Peptidase Inhibition and Analysis (9 papers). Katarzyna Magiera‐Mularz collaborates with scholars based in Poland, Netherlands and Germany. Katarzyna Magiera‐Mularz's co-authors include Tad A. Holak, Alexander Dömlingꝉ, Grzegorz Dubin, P. Grudnik, Bogdan Musielak, Łukasz Skalniak, Krzysztof M. Żak, Katarzyna Guzik, Justyna Kocik-Krol and Dominik Sala and has published in prestigious journals such as Angewandte Chemie International Edition, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Katarzyna Magiera‐Mularz

35 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katarzyna Magiera‐Mularz Poland 18 1.3k 628 565 253 222 37 1.9k
Krzysztof M. Żak Poland 12 1.4k 1.0× 753 1.2× 607 1.1× 313 1.2× 198 0.9× 26 1.9k
Bogdan Musielak Poland 20 1.5k 1.1× 738 1.2× 695 1.2× 333 1.3× 422 1.9× 51 2.3k
Łukasz Skalniak Poland 23 1.0k 0.8× 507 0.8× 816 1.4× 188 0.7× 206 0.9× 53 1.9k
Sifei Han Australia 17 783 0.6× 204 0.3× 511 0.9× 426 1.7× 134 0.6× 28 1.6k
Brent D. G. Page Canada 21 758 0.6× 238 0.4× 723 1.3× 59 0.2× 183 0.8× 52 1.6k
Chenyu Tian China 13 367 0.3× 145 0.2× 738 1.3× 50 0.2× 232 1.0× 24 1.4k
J A Double United Kingdom 15 523 0.4× 185 0.3× 821 1.5× 173 0.7× 191 0.9× 29 1.7k
Taekyu Lee United States 15 401 0.3× 133 0.2× 1.2k 2.1× 45 0.2× 263 1.2× 35 1.6k
Yi Jer Tan China 13 373 0.3× 190 0.3× 694 1.2× 46 0.2× 198 0.9× 24 1.4k
Tracey Clark United States 17 440 0.3× 179 0.3× 578 1.0× 413 1.6× 102 0.5× 22 1.1k

Countries citing papers authored by Katarzyna Magiera‐Mularz

Since Specialization
Citations

This map shows the geographic impact of Katarzyna Magiera‐Mularz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katarzyna Magiera‐Mularz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katarzyna Magiera‐Mularz more than expected).

Fields of papers citing papers by Katarzyna Magiera‐Mularz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katarzyna Magiera‐Mularz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katarzyna Magiera‐Mularz. The network helps show where Katarzyna Magiera‐Mularz may publish in the future.

Co-authorship network of co-authors of Katarzyna Magiera‐Mularz

This figure shows the co-authorship network connecting the top 25 collaborators of Katarzyna Magiera‐Mularz. A scholar is included among the top collaborators of Katarzyna Magiera‐Mularz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katarzyna Magiera‐Mularz. Katarzyna Magiera‐Mularz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kocik-Krol, Justyna, Bogdan Musielak, Małgorzata Stec, et al.. (2025). Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy. ACS Medicinal Chemistry Letters. 16(7). 1359–1364.
2.
Zhang, Hua, Jacek Plewka, Caiyun Wu, et al.. (2024). Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors. European Journal of Medicinal Chemistry. 276. 116683–116683. 7 indexed citations
3.
Skalniak, Łukasz, et al.. (2024). An updated patent review on PD-1/PD-L1 antagonists (2022-present). Expert Opinion on Therapeutic Patents. 34(8). 627–650. 9 indexed citations
4.
Węgrzyn, Katarzyna, Emilia Sikorska, Claire Battin, et al.. (2024). Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer. Translational Oncology. 42. 101892–101892. 3 indexed citations
5.
Czarna, Anna, Barbara Pucelik, Barbara Chruścicka, et al.. (2024). Development of selective ssDNA micro-probe for PD1 detection as a novel strategy for cancer imaging. Scientific Reports. 14(1). 28652–28652.
6.
Surmiak, Ewa, Roberto Butera, Katarzyna Magiera‐Mularz, et al.. (2024). 1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists. RSC Medicinal Chemistry. 15(4). 1210–1215. 1 indexed citations
7.
Donati, Greta, Monica Viviano, Alessandra Cipriano, et al.. (2023). A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors. Archiv der Pharmazie. 357(3). e2300583–e2300583. 2 indexed citations
8.
Butera, Roberto, Marta Requesens, Annechien Plat, et al.. (2023). Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors. Journal of Medicinal Chemistry. 66(14). 9577–9591. 9 indexed citations
9.
Zhang, Hua, Jacek Plewka, Caiyun Wu, et al.. (2023). Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2′-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors. Journal of Medicinal Chemistry. 66(15). 10579–10603. 20 indexed citations
10.
Kitel, Radosław, Ewa Surmiak, Katarzyna Magiera‐Mularz, et al.. (2022). Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments. ACS Chemical Biology. 17(9). 2655–2663. 12 indexed citations
11.
Shaabani, Shabnam, Ewa Surmiak, Roberto Butera, et al.. (2022). Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Molecules. 27(11). 3454–3454. 5 indexed citations
12.
Pucelik, Barbara, Anna Gołda, João Crispim Encarnação, et al.. (2022). Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe. Pharmaceuticals. 15(6). 697–697. 13 indexed citations
13.
Surmiak, Ewa, Katarzyna Magiera‐Mularz, Bogdan Musielak, et al.. (2021). PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action. International Journal of Molecular Sciences. 22(21). 11797–11797. 27 indexed citations
14.
Surmiak, Ewa, Jacek Plewka, Katarzyna Magiera‐Mularz, et al.. (2021). Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction. Journal of Medicinal Chemistry. 64(15). 11614–11636. 61 indexed citations
15.
Musielak, Bogdan, Justyna Kocik-Krol, Łukasz Skalniak, et al.. (2020). Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint. Journal of Medicinal Chemistry. 63(19). 11271–11285. 58 indexed citations
16.
Musielak, Bogdan, et al.. (2020). Competition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions. Molecules. 25(13). 3017–3017. 12 indexed citations
17.
Yang, Jeffrey, Bin Xu, Katarzyna Magiera‐Mularz, et al.. (2019). Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction. Journal of Medicinal Chemistry. 62(15). 7250–7263. 79 indexed citations
18.
Musielak, Bogdan, Justyna Kocik-Krol, Łukasz Skalniak, et al.. (2019). CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 24(15). 2804–2804. 122 indexed citations
19.
Magiera‐Mularz, Katarzyna, Łukasz Skalniak, Krzysztof M. Żak, et al.. (2017). Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint. Angewandte Chemie International Edition. 56(44). 13732–13735. 136 indexed citations
20.
Konstantinidou, Markella, Tryfon Zarganes‐Tzitzikas, Katarzyna Magiera‐Mularz, Tad A. Holak, & Alexander Dömlingꝉ. (2017). Der Immuncheckpoint PD‐1/PD‐L1: Gibt es Therapieoptionen jenseits der Antikörper?. Angewandte Chemie. 130(18). 4932–4940. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krzysztof M. Żak Breakdown of academic impact, for papers by Bogdan Musielak Breakdown of academic impact, for papers by Łukasz Skalniak Breakdown of academic impact, for papers by Sifei Han Breakdown of academic impact, for papers by Brent D. G. Page Breakdown of academic impact, for papers by Chenyu Tian Breakdown of academic impact, for papers by J A Double Breakdown of academic impact, for papers by Taekyu Lee Breakdown of academic impact, for papers by Yi Jer Tan Breakdown of academic impact, for papers by Tracey Clark
Rankless by CCL
2026